Silencing rapsyn in vivo decreases acetylcholine receptors and augments sodium channels and secondary postsynaptic membrane folding

Neurobiology of Disease

Volumn 35, Issue 1, 2009, Pages 14-23

  Martínez Martínez, Pilar ^a   Phernambucq, Marko ^a   Steinbusch, Laura ^a   Schaeffer, Laurent ^b   Berrih Aknin, Sonia ^c   Duimel, Hans ^a   Frederik, Peter ^a   Molenaar, Peter ^a   De Baets, Marc H ^a,d   Losen, Mario ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Ecl Normale Sup de Lyon   (France)

^c CNRS   (France)

^d HASSELT UNIVERSITY   (Belgium)

Author keywords

Congenital myasthenic syndromes; Myasthenia gravis; Neuromuscular junction; Rapsyn; Voltage gated sodium channel

Indexed keywords

CHOLINERGIC RECEPTOR; RAPSYN; SHORT HAIRPIN RNA; SODIUM CHANNEL;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE SILENCING; HALF LIFE TIME; IN VIVO STUDY; MUSCLE; NEUROMUSCULAR SYNAPSE; NEUROMUSCULAR TRANSMISSION; NONHUMAN; NUCLEOTIDE SEQUENCE; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN METABOLISM; RAT;

ANIMALS; ANTIBODIES; BUNGAROTOXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROMYOGRAPHY; ELECTROPORATION; EXCITATORY POSTSYNAPTIC POTENTIALS; FEMALE; GENE EXPRESSION REGULATION; GREEN FLUORESCENT PROTEINS; MICROSCOPY, CONFOCAL; MICROSCOPY, IMMUNOELECTRON; MUSCLE PROTEINS; MUSCLE, SKELETAL; NEUROMUSCULAR JUNCTION; PATCH-CLAMP TECHNIQUES; RATS; RATS, INBRED LEW; RECEPTORS, CHOLINERGIC; RNA, SMALL INTERFERING; SODIUM CHANNELS;

EID: 67349104136     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2009.03.008     Document Type: Article

References (71)

1. Asher O., et al. Increased gene expression of acetylcholine receptor and myogenic factors in passively transferred experimental autoimmune myasthenia gravis. J. Immunol. 151 (1993) 6442-6450
2. Bezakova G., et al. Neural agrin controls acetylcholine receptor stability in skeletal muscle fibers. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9924-9929
3. Bloch R.J., and Froehner S.C. The relationship of the postsynaptic 43K protein to acetylcholine receptors in receptor clusters isolated from cultured rat myotubes. J. Cell. Biol. 104 (1987) 645-654
4. Blow N. RNAi technologies: a screen whose time has arrived. Nat. Methods 5 (2008) 361-366
5. Brockhausen J., et al. Neural agrin increases postsynaptic ACh receptor packing by elevating rapsyn protein at the mouse neuromuscular synapse. Dev. Neurobiol. 68 (2008) 1153-1169
6. Brown K., and Samarsky D. RNAi off-targeting: light at the end of the tunnel. Journal of RNAi and Gene Silencing 2 (2006) 175-177
7. Brummelkamp T.R., et al. A system for stable expression of short interfering RNAs in mammalian cells. Science 296 (2002) 550-553
8. Burke G., et al. Rapsyn mutations in hereditary myasthenia: distinct early- and late-onset phenotypes. Neurology 61 (2003) 826-828
9. Chen F., et al. Rapsyn interaction with calpain stabilizes AChR clusters at the neuromuscular junction. Neuron 55 (2007) 247-260
10. Cossins J., et al. Diverse molecular mechanisms involved in AChR deficiency due to rapsyn mutations. Brain 129 (2006) 2773-2783
11. Culican S.M., et al. Axon withdrawal during synapse elimination at the neuromuscular junction is accompanied by disassembly of the postsynaptic specialization and withdrawal of Schwann cell processes. J. Neurosci. 18 (1998) 4953-4965
12. De Baets M., et al. Immunoregulation in experimental autoimmune myasthenia gravis-about T cells, antibodies, and endplates. Ann. N.Y. Acad. Sci. 998 (2003) 308-317
13. DeChiara T.M., et al. The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell 85 (1996) 501-512
14. Dunne V., and Maselli R.A. Identification of pathogenic mutations in the human rapsyn gene. J. Hum. Genet. 48 (2003) 204-207
15. Elbashir S.M., et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
16. Engel A.G., and Sine S.M. Current understanding of congenital myasthenic syndromes. Curr. Opin. Pharmacol. 5 (2005) 308-321
17. Engel A.G., et al. Experimental autoimmune myasthenia gravis: a sequential and quantitative study of the neuromuscular junction ultrastructure and electrophysiologic correlations. J. Neuropathol. Exp. Neurol. 35 (1976) 569-587
18. Engel A.G., et al. The motor end plate in myasthenia gravis and in experimental autoimmune myasthenia gravis. A quantitative ultrastructural study. Ann. N.Y. Acad. Sci. 274 (1976) 60-79
19. + channels and ankyrin in neuromuscular junctions is complementary to that of acetylcholine receptors and the 43 kd protein. Neuron 3 (1989) 163-175
20. Gautam M., et al. Distinct phenotypes of mutant mice lacking agrin, MuSK, or rapsyn. Brain Res. Dev. Brain Res. 114 (1999) 171-178
21. Gautam M., et al. Defective neuromuscular synaptogenesis in agrin-deficient mutant mice. Cell 85 (1996) 525-535
22. Gautam M., et al. Failure of postsynaptic specialization to develop at neuromuscular junctions of rapsyn-deficient mice. Nature 377 (1995) 232-236
23. Gervasio O.L., et al. Developmental increase in the amount of rapsyn per acetylcholine receptor promotes postsynaptic receptor packing and stability. Dev. Biol. 305 (2007) 262-275
24. Gervasio O.L., and Phillips W.D. Increased ratio of rapsyn to ACh receptor stabilizes postsynaptic receptors at the mouse neuromuscular synapse. J. Physiol. 562 (2005) 673-685
25. Gomez C.M., et al. A beta-subunit mutation in the acetylcholine receptor channel gate causes severe slow-channel syndrome. Ann. Neurol. 39 (1996) 712-723
26. Hantai D., et al. Congenital myasthenic syndromes. Curr. Opin. Neurol. 17 (2004) 539-551
27. Hesselmans L.F., et al. Secondary changes of the motor endplate in Lambert-Eaton myasthenic syndrome: a quantitative study. Acta Neuropathol. 83 (1992) 202-206
28. Hoedemaekers A., et al. Role of the target organ in determining susceptibility to experimental autoimmune myasthenia gravis. J. Neuroimmunol. 89 (1998) 131-141
29. Hoedemaekers A., et al. Age- and sex-related resistance to chronic experimental autoimmune myasthenia gravis (EAMG) in Brown Norway rats. Clin. Exp. Immunol. 107 (1997) 189-197
30. Hoedemaekers A., et al. Age-related susceptibility to experimental autoimmune myasthenia gravis: immunological and electrophysiological aspects. Muscle Nerve 20 (1997) 1091-1101
31. Hsieh A.C., et al. A library of siRNA duplexes targeting the phosphoinositide 3-kinase pathway: determinants of gene silencing for use in cell-based screens. Nucleic Acids Res. 32 (2004) 893-901
32. Ioos C., et al. Congenital myasthenic syndrome due to rapsyn deficiency: three cases with arthrogryposis and bulbar symptoms. Neuropediatrics 35 (2004) 246-249
33. Jackson A.L., et al. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21 (2003) 635-637
34. Janssen S.P., et al. Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil. J. Neuroimmunol. 201-202 (2008) 111-120
35. Kim N., et al. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell. 135 (2008) 334-342
36. Kimura J. Electrodiagnosis in Diseases of Nerve and Muscle: Principles and Practice (2001), Oxford University Press, Oxford
37. Kong X.C., et al. Inhibition of synapse assembly in mammalian muscle in vivo by RNA interference. EMBO Rep. 5 (2004) 183-188
38. Li X.M., et al. Retrograde regulation of motoneuron differentiation by muscle beta-catenin. Nat. Neurosci. 11 (2008) 262-268
39. Lin W., et al. Neurotransmitter acetylcholine negatively regulates neuromuscular synapse formation by a Cdk5-dependent mechanism. Neuron 46 (2005) 569-579
40. Losen M., et al. Treatment of myasthenia gravis by preventing acetylcholine receptor modulation. Ann. N.Y. Acad. Sci. 1132 (2008) 174-179
41. Losen M., et al. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis. Brain 128 (2005) 2327-2337
42. Marchand S., et al. Rapsyn escorts the nicotinic acetylcholine receptor along the exocytic pathway via association with lipid rafts. J. Neurosci. 22 (2002) 8891-8901
43. Martin A.R. Amplification of neuromuscular-transmission by postjunctional folds. Proc. R. Soc. Lond., B Biol. Sci. 258 (1994) 321-326
44. Martinez-Martinez P., et al. Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis. Am. J. Pathol. 170 (2007) 644-657
45. Maselli R.A., et al. Rapsyn mutations in myasthenic syndrome due to impaired receptor clustering. Muscle Nerve 28 (2003) 293-301
46. Maselli R.A., et al. Presynaptic failure of neuromuscular transmission and synaptic remodeling in EA2. Neurology 61 (2003) 1743-1748
47. Misgeld T., et al. Agrin promotes synaptic differentiation by counteracting an inhibitory effect of neurotransmitter. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 11088-11093
48. Molenaar P.C., et al. A non-immunogenic myasthenia gravis model and its application in a study of transsynaptic regulation at the neuromuscular junction. Eur. J. Pharmacol. 196 (1991) 93-101
49. Muller J.S., et al. Rapsyn N88K is a frequent cause of congenital myasthenic syndromes in European patients. Neurology 60 (2003) 1805-1810
50. Nitkin R.M., et al. Identification of agrin, a synaptic organizing protein from Torpedo electric organ. J. Cell. Biol. 105 (1987) 2471-2478
51. Ohno K., et al. Rapsyn mutations in humans cause endplate acetylcholine-receptor deficiency and myasthenic syndrome. Am. J. Hum. Genet. 70 (2002) 875-885
52. Ohno K., et al. E-box mutations in the RAPSN promoter region in eight cases with congenital myasthenic syndrome. Hum. Mol. Genet. 12 (2003) 739-748
53. Pachter B.R., and Eberstein A. Neuromuscular plasticity following limb immobilization. J. Neurocytol. 13 (1984) 1013-1025
54. Pachter B.R., and Eberstein A. The effect of limb immobilization and stretch on the fine structure of the neuromuscular junction in rat muscle. Exp. Neurol. 92 (1986) 13-19
55. Reynolds A., et al. Induction of the interferon response by siRNA is cell type- and duplex length-dependent. RNA 12 (2006) 988-993
56. Roorda B.D., et al. DGAT1 overexpression in muscle by in vivo DNA electroporation increases intramyocellular lipid content. J. Lipid Res. 46 (2005) 230-236
57. Ruff R.L., and Lennon V.A. End-plate voltage-gated sodium channels are lost in clinical and experimental myasthenia gravis. Ann. Neurol. 43 (1998) 370-379
58. Ruff R.L., and Lennon V.A. How myasthenia gravis alters the safety factor for neuromuscular transmission. J Neuroimmunol. 201-202 (2008) 13-20
59. Santa T., et al. Histometric study of neuromuscular junction ultrastructure. II. Myasthenic syndrome. Neurology 22 (1972) 370-376
60. Seybold M.E., et al. Experimental autoimmune myasthenia: clinical, neurophysiologic, and pharmacologic aspects. Ann. N.Y. Acad. Sci. 274 (1976) 275-282
61. Sledz C.A., et al. Activation of the interferon system by short-interfering RNAs. Nat. Cell. Biol. 5 (2003) 834-839
62. Sroka H., et al. Ultrastructure of the syndrome of continuous muscle fibre activity. Acta Neuropathol. 31 (1975) 85-90
63. Toyka K.V., et al. Myasthenia gravis: passive transfer from man to mouse. Science 190 (1975) 397-399
64. Tuschl T., et al. Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev. 13 (1999) 3191-3197
65. VanSaun M., et al. Structural alterations at the neuromuscular junctions of matrix metalloproteinase 3 null mutant mice. J. Neurocytol. 32 (2003) 1129-1142
66. Verschuuren J.J., et al. Single-fiber electromyography in experimental autoimmune myasthenia gravis. Muscle Nerve 13 (1990) 485-492
67. Wood S.J., and Slater C.R. Action potential generation in rat slow- and fast-twitch muscles. J. Physiol. 486 Pt 2 (1995) 401-410
68. Wood S.J., and Slater C.R. The contribution of postsynaptic folds to the safety factor for neuromuscular transmission in rat fast- and slow-twitch muscles. J. Physiol. 500 Pt 1 (1997) 165-176
69. Wood S.J., and Slater C.R. Safety factor at the neuromuscular junction. Prog. Neurobiol. 64 (2001) 393-429
70. Zhang B., et al. Beta-catenin regulates acetylcholine receptor clustering in muscle cells through interaction with rapsyn. J. Neurosci. 27 (2007) 3968-3973
71. Zhang B., et al. LRP4 serves as a coreceptor of agrin. Neuron 60 (2008) 285-297